| | Business Summary | | KOS
Pharmaceuticals,
Inc.
is
a
fully
integrated
specialty
pharmaceutical
company
engaged
in
the
development
of
proprietary
prescription
products
for
the
treatment
of
chronic
cardiovascular
and
respiratory
diseases.
The
Company
manufactures
its
lead
product,
Niaspan,
and
markets
such
product
directly
through
its
own
specialty
sales
force.
Additionally,
the
Company
markets
two
complementary
anti-hypertensive
products,
Mavik
and
Tarka,
through
a
co-promotion
alliance
with
Knoll
Pharmaceutical
Company.
The
Company's
cardiovascular
products
under
development
consist
of
controlled-release,
once-a-day,
oral
dosage
formulations.
The
Company's
respiratory
products
under
development
consist
of
aerosolized
inhalation
formulations
to
be
used
primarily
with
the
Company's
proprietary
inhalation
devices. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | KOS
Pharmaceuticals
is
engaged
primarily
in
the
devel.
of
proprietary
prescription
pharmaceuticals
for
the
treatment
of
certain
chronic
cardiovascular
and
respiratory
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
54%
to
$36.3
million.
Net
loss
fell
16%
to
$19.6
million.
Revenues
reflect
an
increase
in
retail
prescriptions
for
Niaspan(R)
and
growth
of
co-promotion
revenues
with
Abbot
Labs.
Lower
loss
benefited
from
improved
operating
efficiencies. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Daniel Bell, 58
Chairman,
CEO | $622K | -- | Adrian Adams, 50
Pres,
COO | -- | -- | Robert Baldini, 70
Vice
Chairman, Chief Sales and Marketing Officer | 375K | $299K | David Bova, 55
Sr.
VP, R&D | 804K | 1.2M | John Hampilos, 41
VP
of Marketing | -- | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/k/kosp.gif)